Merve Tokoçin

Dr. Merve Tokoçin

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Cureus
Verified
Journal Article
Open access
NHNadir Adnan Hacım
Nadir Adnan Hacım
AAAhmet Akbas
Ahmet Akbas
YUYigit Ulgen
Yigit Ulgen
TATalar Vartanoglu Aktokmakyan
Talar Vartanoglu Aktokmakyan
SMserhat meric
serhat meric
YAYuksel Altinel
Yuksel Altinel
Introduction: Although fine-needle aspiration biopsy (FNAB) with cytologic interpretation using the Bethesda System for Reporting Thyroid Cytopathology has been widely used for thyroid nodules, its efficiency in Bethesda categories of III, IV, and V has been questioned due to variable risk of malignancy. We aimed to evaluate the impact of radiological parameters in Bethesda category III, IV, and V for thyroid malignancy. Methods: We performed a retrospective review of patients with Bethesda category III, IV, and V, and subsequent thyroidectomy. Demographic, ultrasonographic, and clinical variables were recorded. Independent variables for thyroid malignancy and the predictive power of imaging findings were analyzed. Results: There were 159 patients with a mean age of 48.1±13.4 years. Hypoechogenicity of the index nodule was the most common finding in 87 patients (54.7%). There were 74 (46.5%), 34 (21.4%), and 51 patients (32.1%) with Bethesda III, IV, and V categories, respectively. There were 91 patients (57.2%) with a diagnosis of thyroid malignancy. Overall malignant pathology was detected in 18 (24.3%), 25 (73.5%), and 48 patients (94.1%) in Bethesda III, IV, and V categories, respectively (p=0.001). The presence of solitary nodule, hypoechogenicity, and solid structure of index nodule and Bethesda category IV and V were significant variables for final malignant pathology (p<0.05 for all). Conclusion: Hypoechogenicity and solid structure in a solitary index nodule should be regarded as significant ultrasonographic findings for thyroid malignancy. Bethesda category IV and V were also significantly associated with malignancy.

24 March 2026 in European Journal of Breast Health
Verified
Journal Article
Open access
PDF file
Merve TokoçinMerve Tokoçin
Merve Tokoçin
TPTuran Pehlivan
Turan Pehlivan
SCSelçuk Cin
Selçuk Cin
BTBülent Toksöz
Bülent Toksöz
OTOnur Tokoçin
Onur Tokoçin
AÇAtilla Çelik
Atilla Çelik
Evaluating the Role of Artificial Intelligence in Enhancing Multidisciplinary Team Decisions for Breast Cancer Management - European Journal of Breast Health

14 January 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
NBNAIL BESLI
NAIL BESLI
NENilufer Ercin
Nilufer Ercin
Merve TokoçinMerve Tokoçin
Merve Tokoçin
SBSÜMEYRA BÖLÜK
SÜMEYRA BÖLÜK
RÇRabia Kalkan Çakmak
Rabia Kalkan Çakmak
YTYusuf Tutar
Yusuf Tutar
Background/Objectives: Cancer-associated fibroblasts (CAFs) are key stromal mediators of breast tumor progression and therapy resistance. Carvacrol, a dietary monoterpenic phenol, exhibits antiproliferative activity in cancer cells, but its effects on primary human breast CAFs remain unclear. This study aimed to determine whether carvacrol selectively induces mitochondria-related apoptotic signaling in breast CAFs while sparing normal fibroblasts (NFs). Methods: Primary fibroblast cultures were established from invasive ductal carcinoma tissues (CAFs, n = 9) and nonmalignant breast tissues (NFs, n = 5) and validated by α-SMA and FAP immunofluorescence. Cells were exposed to 400 μM carvacrol. Apoptosis was assessed by TUNEL assay and BAX/BCL-XL Western blotting. Changes in signaling pathways were evaluated by analyzing PPARα/NF-κB, sirtuin (SIRT1, SIRT3), autophagy-related markers (LAMP2A, p62), and matrix metalloproteinases (MMP-2, MMP-3). In silico molecular docking and 100-ns molecular dynamics simulations were performed to examine interactions between carvacrol and caspase-3 and caspase-9. Results: Carvacrol induced a pronounced, time-dependent apoptotic response in CAFs, with TUNEL-based viability declining to approximately 10% of control levels by 12 h and a marked increase in the BAX/BCL-XL ratio. In contrast, NFs exhibited minimal TUNEL positivity and no significant change in BAX/BCL-XL. In CAFs, but not NFs, carvacrol reduced PPARα expression and NF-κB nuclear localization, increased SIRT1 and SIRT3 levels, selectively suppressed MMP-3 while partially normalizing MMP-2, and altered autophagy-related markers (decreased LAMP2A and accumulation of p62), consistent with autophagic stress and possible impairment of autophagic flux. Computational analyses revealed stable carvacrol binding to caspase-3 and caspase-9 with modest stabilization of active-site loops, supporting caspase-dependent, mitochondria-related apoptosis. Conclusions: Carvacrol selectively targets breast cancer-associated fibroblasts by inducing mitochondria-related apoptotic signaling while largely sparing normal fibroblasts. This effect is accompanied by coordinated modulation of PPARα/NF-κB, sirtuin, autophagy, and MMP pathways. These findings support further evaluation of carvacrol as a microenvironment-directed adjunct in breast cancer therapy.

Verified
Journal Article
Open access
PDF file
ŞBŞahin Bedir
Şahin Bedir
TKTanju Kapagan
Tanju Kapagan
BDBURÇİN ÇAKAN DEMİREL
BURÇİN ÇAKAN DEMİREL
Merve TokoçinMerve Tokoçin
Merve Tokoçin
ÇYÇiğdem Yıldırım
Çiğdem Yıldırım
GEGokmen Umut Erdem
Gokmen Umut Erdem
Background: The prognostic significance of low-level human epidermal growth factor receptor 2 (HER2) expression in hormone receptor-positive/HER2-negative (HR+/HER2−) metastatic breast cancer remains unclear, particularly in patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). This study aimed to evaluate the impact of HER2-low status on treatment response and survival outcomes in this setting. Methods: This multicenter retrospective cohort study included patients with HR+/HER2− metastatic breast cancer who received first-line endocrine therapy combined with palbociclib or ribociclib between January 2018 and May 2025. HER2-low tumors were defined as immunohistochemistry (IHC) 1+ or 2+ with negative in situ hybridization, while HER2-zero tumors were classified as IHC 0. Treatment response, progression-free survival (PFS), and overall survival (OS) were compared between groups using Kaplan–Meier analysis and Cox regression models. Results: A total of 309 patients were analyzed, including 122 (39.5%) with HER2-low disease and 187 (60.5%) with HER2-zero disease. Baseline clinicopathological characteristics were well balanced between groups. The overall response rate was 75.4% in the HER2-low group and 72.7% in the HER2-zero group (p > 0.05). Median PFS was 23.9 months for HER2-low patients and 25.2 months for HER2-zero patients (log-rank p = 0.785). Median OS was 49.5 and 53.1 months, respectively, with no statistically significant difference (log-rank p = 0.649). HER2 status was not an independent predictor of PFS or OS in multivariable analyses. Conclusions: In patients with HR+/HER2− metastatic breast cancer treated with first-line endocrine therapy plus CDK4/6 inhibitors, HER2-low expression was not associated with differences in treatment response or survival outcomes. These findings suggest that HER2-low status does not have prognostic or predictive relevance in this endocrine-sensitive population.

24 March 2026 in European Journal of Breast Health
Verified
Journal Article
Open access
PDF file
ASAtilla Soran
Atilla Soran
Merve TokoçinMerve Tokoçin
Merve Tokoçin
HAHüseyin Özgür Aytaç
Hüseyin Özgür Aytaç
Mehmet Ali Ali NazlıMehmet Ali Ali Nazlı
Mehmet Ali Ali Nazlı
SOSERDAR OZBAS
SERDAR OZBAS
WBWendie A. Berg
Wendie A. Berg
Pittsburgh Classification and Treatment Algorithm for Idiopathic Granulomatous Mastitis: A Multicenter Cohort Study - European Journal of Breast Health

13 October 2023 in Atlas Universitesi Tip ve Saglik Bilimleri Dergisi
Verified
Journal Article
Closed access
Merve TokoçinMerve Tokoçin
Merve Tokoçin
HYHakan Yi̇ğİtBaş
Hakan Yi̇ğİtBaş
AÇAtilla Çelik
Atilla Çelik
Objective:Breast cancer is the most common type of cancer among women, and risk-reducing treatments have gained importance in recent years with the detection of genetic mutations. Method: Patients who underwent prophylactic mastectomy in our clinic between January 2018 and January 2023 were evaluated retrospectively. Surgical procedures performed on all patients, complications developing secondary to the surgery, the time of sending the patients to adjuvant treatment, the necessity of secondary operation, and disease-free survival were evaluated. Results: In 4 of the 15 patients with genetic mutations who underwent prophylactic mastectomy, this surgery was performed before tumor formation. Complications such as capsular contracture, skin necrosis and nipple necrosis developed in 6 patients, and reoperation was required in 4 patients. In the follow-up of all patients, oncological principles were adhered to, and no recurrence or metastasis was observed in any of them. Conclusion:With the expansion of the genetic mutation panel, patients have started to gain time, and as physicians, we need to guide these people in accordance with oncological principles. Prophylactic mastectomy is the method we recommend in this study for tumor-free survival.